Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
![Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-021-04534-8/MediaObjects/277_2021_4534_Fig1_HTML.png)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
![Overall survival in a cohort of multiple myeloma patients treated with... | Download Scientific Diagram Overall survival in a cohort of multiple myeloma patients treated with... | Download Scientific Diagram](https://www.researchgate.net/publication/360723428/figure/fig3/AS:1179937633517568@1658330462138/Overall-survival-in-a-cohort-of-multiple-myeloma-patients-treated-with-DVd.png)
Overall survival in a cohort of multiple myeloma patients treated with... | Download Scientific Diagram
![Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-01440-x/MediaObjects/41598_2021_1440_Fig1_HTML.png)
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
![Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments](https://www.frontiersin.org/files/Articles/624661/fonc-10-624661-HTML/image_m/fonc-10-624661-g001.jpg)
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
![Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/8833ed53-bc97-4a4a-ab63-8684e37f96f7/gr1.jpg)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
![Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5996585/bin/APJON-5-270-g005.jpg)
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC
![Current Oncology | Free Full-Text | Management of Multiple Myeloma: A Review for General Practitioners in Oncology Current Oncology | Free Full-Text | Management of Multiple Myeloma: A Review for General Practitioners in Oncology](https://www.mdpi.com/curroncol/curroncol-30-00334/article_deploy/html/images/curroncol-30-00334-g001.png)
Current Oncology | Free Full-Text | Management of Multiple Myeloma: A Review for General Practitioners in Oncology
Additional Trials | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
![CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram](https://www.researchgate.net/publication/336032148/figure/fig4/AS:807059306078209@1569429341451/CASTOR-study-design-RRMM-relapsed-or-refractory-multiple-myeloma-DVd_Q640.jpg)
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
![Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2021-1176/asset/images/medium/figure2.gif)